FDA-approved small-molecule kinase inhibitors

Trends in Pharmacological Sciences

Volumn 36, Issue 7, 2015, Pages 422-439

  Wu, Peng ^a   Nielsen, Thomas E ^b   Clausen, Mads H ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

cancer; crystal structure; lipid kinase; protein kinase; serine threonine kinase; tyrosine kinase

Indexed keywords

AFATINIB; AXITINIB; BOSUTINIB; CERITINIB; CRIZOTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IBRUTINIB; IMATINIB; LAPATINIB; LENVATINIB; LIPID KINASE INHIBITOR; NILOTINIB; NINTEDANIB; NON RECEPTOR TYROSINE KINASE INHIBITOR; PAZOPANIB; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PONATINIB; REGORAFENIB; RUXOLITINIB; SORAFENIB; SUNITINIB; TOFACITINIB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

AMINO ACID SEQUENCE; BINDING SITE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CHRONIC LYMPHATIC LEUKEMIA; CRYSTAL STRUCTURE; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LARGE CELL LYMPHOMA; LUNG CANCER; MANTLE CELL LYMPHOMA; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; UNITED STATES;

DRUG APPROVAL; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOTRANSFERASES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84933181941     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.04.005     Document Type: Review

References (110)

1. L.N. Johnson, and R.J. Lewis Structural basis for control by phosphorylation Chem. Rev. 101 2001 2209 2242
2. J.A. Adams Kinetic and catalytic mechanisms of protein kinases Chem. Rev. 101 2001 2271 2290
3. M. Rask-Andersen Advances in kinase targeting: current clinical use and clinical trials Trends Pharmacol. Sci. 35 2014 604 620
4. M. Huang Molecularly targeted cancer therapy: some lessons from the past decade Trends Pharmacol. Sci. 35 2014 41 50
5. W.W. Ma, and A.A. Adjei Novel agents on the horizon for cancer therapy CA Cancer J. Clin. 59 2009 111 137
6. C. Sun, and R. Bernards Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies Trends Biochem. Sci. 39 2014 465 474
7. J.D. Clark Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases J. Med. Chem. 57 2014 5023 5038
8. P.J. Barnes New anti-inflammatory targets for chronic obstructive pulmonary disease Nat. Rev. Drug Discov. 12 2013 543 559
9. F. Muth Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases J. Med. Chem. 58 2015 443 456
10. R. Kikuchi An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease Nat. Med. 20 2014 1464 1471
11. A.S. Banks An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ Nature 517 2015 391 395
12. G. Burnett, and E.P. Kennedy The enzymatic phosphorylation of proteins J. Biol. Chem. 211 1954 969 980
13. E.H. Fischer, and E.G. Krebs Conversion of phosphorylase b to phosphorylase a in muscle extracts J. Biol. Chem. 216 1955 121 132
14. E.G. Krebs, and E.H. Fischer The phosphorylase b to a converting enzyme of rabbit skeletal muscle Biochim. Biophys. Acta 20 1956 150 157
15. D.A. Walsh An adenosine 3′,5′-monophosphate-dependant protein kinase from rabbit skeletal muscle J. Biol. Chem. 243 1968 3763 3765
16. P. Cohen The origins of protein phosphorylation Nat. Cell Biol. 4 2002 E127 E130
17. L.S. Steelman JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis Leukemia 18 2004 189 218
18. The UniProt Consortium Update on activities at the Universal Protein Resource (UniProt) in 2013 Nucleic Acids Res. 41 2013 D43 D47
19. G. Manning The protein kinase complement of the human genome Science 298 2002 1912 1934
20. E. Pennisi ENCODE project writes eulogy for junk DNA Science 337 2012 1159 1161
21. D. Knighton Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 407 414
22. M. Tong, and M.A. Seeliger Targeting conformational plasticity of protein kinases ACS Chem. Biol. 10 2015 190 200
23. M.E.M. Noble Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805
24. R.A. Norman Structural approaches to obtain kinase selectivity Trends Pharmacol. Sci. 33 2012 273 278
25. K.J. Cox Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases Future Med. Chem. 3 2010 29 43
26. V. Lamba, and I. Ghosh New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors Curr. Pharm. Des. 18 2012 2936 2945
27. P. Yaish Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors Science 242 1988 933 935
28. A. Gazit Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors J. Med. Chem. 32 1989 2344 2352
29. L.K. Gavrin, and E. Saiah Approaches to discover non-ATP site kinase inhibitors MedChemComm 4 2013 41 51
30. Q. Wang A structural atlas of kinases inhibited by clinically approved drugs Methods Enzymol. 548 2014 23 67
31. A. Levitzki Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance Annu. Rev. Pharmacol. Toxicol. 53 2013 161 185
32. B.J. Druker Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Eng. J. Med. 344 2001 1031 1037
33. S. Panjarian Structure and dynamic regulation of Abl kinases J. Biol. Chem. 288 2013 5443 5450
34. G.E. Winter Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML Nat. Chem. Biol. 8 2012 905 912
35. B. Nagar Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 62 2002 4236 4243
36. A.J. Lamontanara Mechanisms of resistance to BCR-ABL and other kinase inhibitors Biochim. Biophys. Acta 1834 2013 1449 1459
37. L. Ma A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia Sci. Transl. Med. 6 2014 252ra121
38. N.M. Levinson, and S.G. Boxer A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity Nat. Chem. Biol. 10 2014 127 132
39. Y-T. Xuan An essential role of the JAK-STAT pathway in ischemic preconditioning Proc. Natl. Acad. Sci. U.S.A. 98 2001 9050 9055
40. S.C. Meyer, and R.L. Levine Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors Clin. Cancer Res. 20 2014 2051 2059
41. S.J. Divito, and T.S. Kupper Inhibiting Janus kinases to treat alopecia areata Nat. Med. 20 2014 989 990
42. J.D. Doles, and B.B. Olwin The impact of JAK-STAT signaling on muscle regeneration Nat. Med. 20 2014 1094 1095
43. H.L. Geyer, and R.A. Mesa Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood 124 2014 3529 3537
44. J.E. Chrencik Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6 J. Mol. Biol. 400 2010 413 433
45. N.K. Williams Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains J. Mol. Biol. 387 2009 219 232
46. E.R. Goedken Tricyclic covalent inhibitors selectively target Jak3 through an active-site thiol J. Biol. Chem. 298 2014 4573 4589
47. M. Gehringer Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres ChemMedChem 9 2014 2516 2527
48. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 5 2005 341 354
49. P. Littlefield Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations Sci. Signal. 7 2014 ra114
50. A. Citri, and Y. Yarden EGF-ERBB signalling: towards the systems level Nat. Rev. Mol. Cell Biol. 7 2006 505 516
51. C-H. Yun Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227
52. K.S. Gajiwala Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition Structure 21 2013 209 219
53. J. Stamos Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor (erlotinib with EGFR) J. Biol. Chem. 277 2002 46265 46272
54. E.R. Wood A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64 2004 6652 6659
55. C. Qiu Mechanism of activation and inhibition of the HER4/ErbB4 kinase Structure 16 2008 460 467
56. Z. Fang Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features ACS Chem. Biol. 8 2013 58 70
57. Z. Zhao Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 9 2014 1230 1241
58. P.P. Knowles Structure and chemical inhibition of the RET tyrosine kinase domain J. Biol. Chem. 281 2006 33577 33587
59. N. Ferrara The biology of VEGF and its receptors Nat. Med. 9 2003 669 676
60. B. Olofsson Vascular endothelial growth factor B, a novel growth factor for endothelial cells Proc. Natl. Acad. Sci. U.S.A. 93 1996 2576 2581
61. M. McTigue Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors Proc. Natl. Acad. Sci. U.S.A. 109 2012 18281 18289
62. J.R. Simard Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors J. Am. Chem. Soc. 131 2009 13286 13296
63. P.A. Harris Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor J. Med. Chem. 51 2008 4632 4640
64. K. Okamoto Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization ACS Med. Chem. Lett. 6 2015 89 94
65. R. Chiarle The anaplastic lymphoma kinase in the pathogenesis of cancer Nat. Rev. Cancer 8 2008 11 23
66. M.M. Awad, and A.T. Shaw ALK inhibitors in non-small cell lung cancer: crizotinib and beyond Clin. Adv. Hematol. Oncol. 12 2014 429 439
67. M.M. Awad Acquired resistance to crizotinib from a mutation in CD74-ROS1 N. Eng. J. Med. 368 2013 2395 2401
68. J.J. Cui Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 54 2011 6342 6363
69. A.T. Shaw Ceritinib in ALK-rearranged non-small-cell lung cancer N. Eng. J. Med. 370 2014 1189 1197
70. L. Friboulet The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Cancer Discov. 4 2014 662 673
71. J. Stamos Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor EMBO J. 23 2004 2325 2335
72. C. Basilico A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met J. Biol. Chem. 283 2008 21267 21277
73. L. Trusolino MET signalling: principles and functions in development, organ regeneration and cancer Nat. Rev. Mol. Cell Biol. 11 2010 834 848
74. F. Gelsomino MET and small-cell lung cancer Cancers 6 2014 2100 2115
75. R. Katayama Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer Clin. Cancer Res. 21 2015 166 174
76. F. Solca Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J. Pharmacol. Exp. Ther. 343 2012 342 350
77. R.W. Hendriks Targeting Bruton's tyrosine kinase in B cell malignancies Nat. Rev. Cancer 14 2014 219 232
78. J.C. Byrd Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N. Eng. J. Med. 369 2013 32 42
79. K. Garber Kinase inhibitors overachieve in CLL Nat. Rev. Drug Discov. 13 2014 162 164
80. D.J. Marcotte Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases Protein Sci. 19 2010 429 439
81. G. Bollag Vemurafenib: the first drug approved for BRAF-mutant cancer Nat. Rev. Drug Discov. 11 2012 873 886
82. P.T.C. Wan Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
83. G. Bollag Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
84. M. Pulici Optimization of diarylthiazole B-Raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect ChemMedChem 10 2014 276 295
85. J.J. Luke The biology and clinical development of MEK inhibitors for cancer Drugs 74 2014 2111 2128
86. H. Abe Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate) ACS Med. Chem. Lett. 2 2011 320 324
87. Q. Dong Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer Bioorg. Med. Chem. Lett. 21 2011 1315 1319
88. K.T. Flaherty Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N. Eng. J. Med. 367 2012 1694 1703
89. G.V. Long Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N. Eng. J. Med. 371 2014 1877 1888
90. P. Wu, and Y.Z. Hu PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress Curr. Med. Chem. 17 2010 4326 4341
91. F. Chiarini Current treatment strategies for inhibiting mTOR in cancer Trends Pharmacol. Sci. 36 2015 124 135
92. Y.J. Choi, and L. Anders Signaling through cyclin D-dependent kinases Oncogene 33 2014 1890 1903
93. M.C. Casimiro Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present Expert Opin. Investig. Drugs 23 2014 295 304
94. H. Lu, and U. Schulze-Gahmen Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition J. Med. Chem. 49 2006 3826 3831
95. M. Whitman Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation Nature 315 1985 239 242
96. P. Wu PI3K inhibitors for cancer therapy: what has been achieved so far? Curr. Med. Chem. 16 2009 916 930
97. R.R. Furman Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N. Eng. J. Med. 370 2014 997 1007
98. B.D. Cheson CLL and NHL: the end of chemotherapy? Blood 123 2014 3368 3370
99. 3K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer Nature 510 2014 407 411
100. 3K inhibitors Nat. Chem. Biol. 6 2010 117 124
101. J.R. Somoza Structural, biochemical and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ J. Biol. Chem. 290 2015 8439 8446
102. P. Wu, and Y. Hu Small molecules targeting phosphoinositide 3-kinases MedChemComm 3 2012 1337 1355
103. I.W. Flinn Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma Blood 123 2014 3406 3413
104. J.R. Brown Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia Blood 123 2014 3390 3397
105. D.A. Fruman, and C. Rommel PI3K and cancer: lessons, challenges and opportunities Nat. Rev. Drug Discov. 13 2014 140 156
106. C. Costa Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer Cancer Cell 27 2015 97 108
107. S. Schwartz Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ Cancer Cell 27 2015 109 122
108. M.S. Kinch An analysis of FDA-approved drugs for oncology Drug Discov. Today 19 2014 1831 1835
109. M.I. Davis Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1046 1051
110. M. Rask-Andersen The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication Annu. Rev. Pharmacol. Toxicol. 54 2014 9 26